Search results
Showing 646 to 660 of 2008 results for nice guidelines
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers...
In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.
Myocardial infarction: medication for MI more than 12 months ago (IND126)
This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers...
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
How to register as a stakeholder with NICE.
How to register as a stakeholder with NICE.
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.
We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.
Awaiting development Reference number: GID-QS10035 Expected publication date: TBC